Cancer | Target Ag | Study model | Results | References |
---|---|---|---|---|
Triple-negative breast cancer (TNBC) | HER1 HER2 | In vitro In vivo | Induction of HS578T, MDA-MB-468, MDA-MB-231, and MCF-7 cell line elimination in vitro Inhibition of the development of xenograft TNBC tumors in mice | |
Non-small-cell lung carcinoma (NSCLC) | NA | In vitro In vivo | Selective eradication of A549, H23, and H1299 cell lines in vitro Abrogated tumor progress of xenografts NSCLC in mice | [158] |
Glioblastoma | EGFRvIII | In vitro In vivo | Stimulation of non-significant anti-tumor response against the heterogeneous EGFRvIII expressing tumors | [159] |
Mammary cancer | HER2 | In vivo | PTPN2 ablation in T cells improved anti‐tumor response and CAR T‐cell efficacy in mice xenografts | [160] |
Glioblastoma | EGFRvIII | In vivo | Selective elimination of EGFR-expressing tumor cells in U87 glioma cell bearing NSG mice | [161] |
Melanoma | HER2 | In vitro In vivo | Elimination of SK-MEL-1 cell line in vitro Profound or complete abrogation of tumor progress in xenograft tumors in mice | [162] |
Glioblastoma | EGFRvIII | In vivo | Stimulation of antigen loss and also adaptive resistance in patients with recurrent glioblastoma upon infusion of a single dose of EGFRvIII-specific CAR T cells | [163] |
Glioblastoma | HER2 | In vitro In vivo | Tandem CAR T cells affecting HER2 and IL13Rα2 attenuated tumor antigen escape in vitro and in vivo | [164] |
Squamous cell carcinoma (SCC) | NA | In vitro | Selective eradication of FaDu cells in vitro | [165] |
Pancreatic ductal adenocarcinoma (PDA) | HER2 | In vivo | Switchable CAR-T cells trailed by injection of a Fab-based switch directed against HER2 showed higher efficacy against the advanced pancreatic tumors in NSG mice | [121] |
Glioblastoma | EGFRvIII | In vivo | Intra-tumoral IL-12 delivery boosted the efficacy of CAR-T cell immunotherapy in tumor cell bearing C57Bl/6 mice | [166] |
Glioblastoma | EGFRvIII | In vitro In vivo | Notable antitumor impacts of EGFRvIII-specific CAR-T cell therapy along with PD-1 checkpoint blockade in glioblastoma cells | |
NSCLC | NA | In vivo | Verification of the safety and feasibility of EGFR-specific CART cell against EGFR-positive NSCLC | [168] |
Glioblastoma | EGFRvIII | In vivo | PD-1 ablation using CRISPR-Cas9 led to the ameliorated anti-tumor function of EGFRvIII-specific CAR T cells in tumor cell bearing mice | |
Ovarian cancer | HER2 | In vivo | Low-affinity (LA)-CARTs demonstrated lower liver injury and less systemic rates of IFN-γ than high-affinity (HA)-CARTs in xenograft mice | [171] |
NSCLC | HER2 | In vivo | Docetaxel (DOC) improved the infiltration of HER2-CAR T cells to tumor area in the NSCLC mice model | [172] |
Various tumors | HER2 | In vitro In vivo | HA-CAR T cells produced higher rates of IFN-γ and IL-2 than LA-CAR T cells | [173] |
Head and neck squamous cell carcinomas (HNSCC) | NA | In vitro In vivo | EGFR-specific CAR T cells considerably reserved the proliferation of radio-resistant Cal33 tumor cells in vitro and mice xenografts | [174] |
Glioblastoma | EGFRvIII | In vivo | EGFRvIII-specific CAR T cells reduced tumor development in mice xenografts | [175] |
Various tumors | HER2 | In vitro | HER2Bi-armed CART19 showed selective cytotoxicity versus various HER2+/EGFR+/CD19- breast, pancreatic, ovarian, prostate, and lung cancer cell lines | [123] |
NSCLC | EGFRvIII | In vitro In vivo | Efficient antitumor function versus A549 cell line in vitro and in vivo | [176] |
Various tumors | HER2 | In vivo | Restoring the antitumor impacts of HER2-specific CAR T cells by delaying epithelial-mesenchymal transition in tumor cells | [177] |
Sarcoma | HER2 | In vivo | Verification of the safety and efficacy of HER2-specific CAR T cells in patients with sarcoma for 6 weeks lacking apparent toxicities | [178] |
Hepatocellular carcinoma (HCC) | EGFRvIII | In vitro In vivo | EGFRvIII-specific CAR T cells established by piggyBac transposon displayed robust growth suppression versus HCC cell lines in vitro and in vivo | [179] |
NSCLC | NA | In vivo | Verification of the safety and efficacy of EGFR-specific CAR T cells against EGFR-positive NSCLC patients | [180] |
Ovarian cancer | HER2 | In vitro | Inhibition of tumor cells proliferation by HER2-specific CAR-T cells | [181] |
Colorectal cancer (CRC) | HER2 | In vivo | Regression or elimination of CRC xenograft in tumor cell bearing NOD-NPG mice | [139] |
Breast cancer | HER2 | In vivo | A small population of HER2-specific CAR T cells could stimulate an anti-tumor response against breast cancer xenografts | [182] |
Glioblastoma | EGFRvIII | In vivo | EGFRvIII-specific CAR T cells showed no clinically significant effect in patients with glioblastoma | [183] |
TNBC | NA | In vitro In vivo | Combination therapy with THZ1 and EGFR CAR T cells restored immune resistance, reduced tumor proliferation, and also metastasis in TNBC xenografts | [184] |
HCC | NA | In vitro In vivo | EGFR-specific CAR T cells demonstrated poor proliferation activity and cytotoxicity versus HCC cells | [185] |
Gastric cancer | HER2 | In vitro In vivo | Robust cytotoxicity against HER2-positive gastric cancer cells | [141] |